Skip to main content

20-01-2020 | Oncology | News | Article


First-line ramucirumab–erlotinib supported by EMA for metastatic NSCLC

Lynda Williams

medwireNews: The EMA has adopted a positive opinion recommending use of the VEGFR2 inhibitor ramucirumab as a first-line treatment for metastatic non-small-cell lung cancer (NSCLC) alongside the EGFR inhibitor erlotinib.

The indication follows findings from the RELAY study of treatment-naïve patients with EGFR-mutated NSCLC showing a significant improvement in progression-free survival (PFS) with the combination versus placebo plus erlotinib.

Ramucirumab may also be used alongside docetaxel in Europe for the treatment of locally advanced or metastatic NSCLC that has progressed after platinum-based chemotherapy, as well as for the treatment of gastric, colorectal, and liver cancer.

And the ongoing RANGE trial suggests that the addition of ramucirumab  to docetaxel may extend PFS but not overall survival in patients with platinum-refractory advanced urothelial carcinoma.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature group

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits